inflammation/protease

TECHNICAL FIELD The invention relates to the field of treatment of conditions characterized by inflammation or inflammatory responses. More specifically, it concerns treatment of inflammation and inflammatory diseases with protease nexin- 1. BACKGROUND ART The structure and recombinant production of

BACKGROUND OF THE INVENTION The present invention relates to an anti-inflammatory agent comprising as an active component a human urinary thiol protease inhibitor and a process for preparation thereof. Human urinary proteins are composed mainly of albumin [see "Sogo Rinsho", Vol. 27, P. 1223

BACKGROUND OF THE INVENTION 1. Field of the Invention This invention relates to a novel class of heterocyclic compounds useful for selectively inhibiting trypsin-like enzymes, selectively inhibiting chymotrypsin-like enzymes, selectively inhibiting elastase or for generally inhibiting serine

FIELD OF THE INVENTION This invention relates to the use of cyclic peptides for modulating cytokine activity, including signaling and inflammatory pathways, in various diseases. More particularly, cyclic peptides possess hereto unknown biological activities, such as inhibition of sheddases and other

BACKGROUND OF THE INVENTION 1. Field of the Invention This invention relates to a novel class of heterocyclic compounds useful for selectively inhibiting trypsin-like enzymes, selectively inhibiting chymotrypsin-like enzymes, selectively inhibiting elastase or for generally inhibiting serine

BACKGROUND OF THE INVENTION 1. Field of the Invention This invention relates to a novel class of heterocyclic compounds useful for selectively inhibiting trypsin-like enzymes, selectively inhibiting chymotrypsin-like enzymes, selectively inhibiting elastase or for generally inhibiting serine

This invention relates to inhibitors of cysteine proteases, in particular to heteroaryl nitrile cathepsin K inhibitors and to their pharmaceutical use for the treatment or prophylaxis of diseases or medical conditions in which cathepsin K is implicated. Cathepsin K is a member of the family of

BACKGROUND OF THE INVENTION Serine proteases are a group of endopeptidase enzymes which have a serine amino acid in their active center. Representative serine proteases include trypsin, thrombin, and plasmin related to blood coagulation and the fibrinolysis system (Chem. Pharm. Bull., 41(1):117

FIELD OF THE INVENTION The present invention relates to a method and composition for treating mammals afflicted with inflammatory diseases or injuries. More particularly, the present invention relates to the treatment of certain inflammatory conditions in patients, by administering serine protease

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates generally to programmed cell death and specifically to compositions and methods for ameliorating or preventing inflammation and symptoms associated therewith using interleukin-1.beta.-converting enzyme (ICE)/CED-3

DESCRIPTION OF THE FIELD Tryptase, the predominant protease secreted from human mast cells, is thought to be involved in neuropeptide processing and tissue inflammation. Tryptase concentrations are elevated in the bloodstream for several hours following anaphylaxis (Schwartz et al. (1987) N. Eng. J.

REFERENCE TO SEQUENCE LISTING The Sequence Listing submitted Oct. 11, 2018 as a text file named "21101_0371U3_Revised_Sequence_Listing.txt," created on Oct. 9, 2018, and having a size of 2,454 bytes is hereby incorporated by reference pursuant to 37 C.F.R. .sctn. 1.52(e)(5). TECHNICAL FIELD The

REFERENCE TO SEQUENCE LISTING The Sequence Listing submitted Jun. 19, 2019 as a text file named "21101_0371U4_Updated_Sequence_Listing.txt," created on Apr. 3, 2019, and having a size of 2,497 bytes is hereby incorporated by reference pursuant to 37 C.F.R. .sctn. 1.52(e)(5). TECHNICAL FIELD The

FIELD OF THE INVENTION This invention relates to compositions containing a mast cell protease inhibitor and methods for use thereof in the prevention and treatment of inflammatory disorders mediated by mast cell tryptases. Methods utilizing the compositions for identifying additional inhibitors of

BACKGROUND OF THE INVENTION 1. Field of the Invention This disclosure relates to tripeptide epoxy ketone protease inhibitors including methods of making and using the same. 2. Description of Related Technology In eukaryotes, protein degradation is predominately mediated through the ubiquitin pathway